Evidence map›Paper›PMID 31300820›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.

Andreea A Artenie, Evan B Cunningham, Gregory J Dore, Brian Conway, Olav Dalgard, Jeff Powis, Philip Bruggmann, Margaret Hellard, Curtis Cooper, Philip Read and 12 more

2 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02336139 phase2completednot on this map

A Phase II, Open-label, Single Arm, Multicentre, International Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use

TypeinterventionalSponsorKirby InstituteRan2016 to 2018Enrolled103ConditionsHepatitis CArmsSofosbuvir (SOF)/GS-5816
NCT02498015 phase4completednot on this map

A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy

TypeinterventionalSponsorKirby InstituteRan2016 to 2019Enrolled87ConditionsHepatitis C, ChronicArms"3D" regimen, "3D" regimen with ribavirin
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. High Satisfaction with Patient-Centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-Methods Study.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 7 countries.

Andreea A ArtenieDepartment of Social and Preventive Medicine, School of Public Health, Université de Montréal, Canada.
Evan B CunninghamKirby Institute, University of New South Wales, Australia.
Gregory J DoreKirby Institute, University of New South Wales, Australia.
Brian ConwayVancouver Infectious Diseases Centre, Canada.
Olav DalgardDepartment of Infectious Disease, Akershus University Hospital, Oslo, Norway.
Jeff PowisSouth Riverdale Community Health Centre, Toronto, Canada.
Philip BruggmannArud Centres for Addiction Medicine, Zurich, Switzerland.
Margaret HellardCentre for Population Health, Burnet Institute, Australia.
Curtis CooperOttawa Hospital Research Institute, Canada.
Philip ReadKirby Institute, University of New South Wales, Australia.
Jordan J FeldToronto General Hospital Research Institute, Canada.
Behzad HajarizadehKirby Institute, University of New South Wales, Australia.
Janaki AminKirby Institute, University of New South Wales, Australia.
Karine LacombeDepartment of Infectious and Tropical Diseases, Saint-Antoine Hospital, Paris, France.
Catherine StedmanDepartment of Medicine, University of Otago, New Zealand.
Alain H LitwinDepartment of Medicine, School of Medicine Greenville, University of South Carolina.
Pip MarksKirby Institute, University of New South Wales, Australia.
Gail V MatthewsKirby Institute, University of New South Wales, Australia.
Sophie QuieneKirby Institute, University of New South Wales, Australia.
Amanda ErrattKirby Institute, University of New South Wales, Australia.
Julie BruneauDepartment of Social and Preventive Medicine, School of Public Health, Université de Montréal, Canada.
Jason GrebelyKirby Institute, University of New South Wales, Australia.
UNSW Sydney · AUCentre Hospitalier de l’Université de Montréal · CAAddiction Switzerland · CHAkershus University Hospital · NOBurnet Institute · AUInserm · FROttawa Hospital · CAPrisma Health · USRegent Park Community Health Centre · CAToronto General Hospital · CAUniversity of Otago · NZVancouver Infectious Diseases Centre · CA

Funding

A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (the REACT Study)R01DA040506 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI MATTHEWS, GAIL · 2015 to 2019
$3.7M
NIDA NIH HHS R01 DA040506
6 · The paper itself

Abstract

backgroundIn many settings, recent or prior injection drug use remains a barrier to accessing direct-acting antiviral treatment (DAA) for hepatitis C virus (HCV) infection. We examined patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment (OAT) during and following DAA-based treatment.

methodsSIMPLIFY and D3FEAT are phase 4 trials evaluating the efficacy of DAA among people with past 6-month injecting drug use or receiving OAT through a network of 25 international sites. Enrolled in 2016-2017, participants received sofosbuvir/velpatasvir (SIMPLIFY) or paritaprevir/ritonavir/dasabuvir/ombitasvir ± ribavirin (D3FEAT) for 12 weeks and completed behavioral questionnaires before, during, and up to 2 years posttreatment. The impact of time in HCV treatment and follow-up on longitudinally measured longitudinally measured behaviors was estimated using generalized estimating equations.

resultsAt screening, of 190 participants (mean age, 47 years; 74% male), 62% reported any past-month injecting 16% past-month injection equipment sharing, and 61% current OAT. Median alcohol use was 2 (Alcohol Use Disorders Identification Test-Consumption; range, 1-12). During follow-up, opioid injecting (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.92-0.99) and sharing (OR, 0.87; 95% CI, 0.80-0.94) decreased, whereas no significant changes were observed for stimulant injecting (OR, 0.98; 95% CI, 0.94-1.02) or alcohol use (OR, 0.99; 95% CI, 0.95-1.04).

conclusionsInjecting drug use and risk behaviors remained stable or decreased following DAA-based HCV treatment. Findings further support expanding HCV treatment to all, irrespective of injection drug use. CLINICAL TRIALS REGISTRATION: SIMPLIFY, NCT02336139; D3FEAT, NCT02498015.

Indexed as

Antiviral AgentsHepatitis CHepatitis C, ChronicPharmaceutical PreparationsSubstance Abuse, IntravenousAnalgesics, OpioidDrug Therapy, CombinationFemaleHepacivirusHumansMaleMiddle AgedRibavirinSustained Virologic ResponseAnalgesics, OpioidAntiviral AgentsPharmaceutical PreparationsRibavirinDAAdrug usehepatitis Cinjecting drug usePWID

Identifiers

PMID31300820
PMCPMC7245153
OpenAlexW2957874784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.